Top Markets
#1 MowCat MowCat +48.86%
#2 Derive Derive +27.61%
#3 Geodnet Geodnet +18.75%
#4 Cross Cross +16.10%
#5 Audiera Audiera +13.75%
#6 Humanity Humanity +11.31%
#7 aPriori aPriori +11.31%
#8 Biconomy Biconomy +10.96%
#9 Quack AI Quack AI +9.85%
#10 Cap Cap +9.35%
Coin of the day
MowCat MowCat
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
Rang in aandelen #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
Aandeelprijs
$1.84
Laatst gesynchroniseerd: 2026-08-11
Marktkapitalisatie
$3.51M
Verandering (1 dag)
0.46%
Verandering (1 jaar)
-62.71%
Land
US
Handel Dogwood Therapeutics, Inc. (DWTX)

Categorie

Healthcare
Winst voor Dogwood Therapeutics, Inc. (DWTX)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Dogwood Therapeutics, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Dogwood Therapeutics, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE